Skip to main content

Table 1 Relationship between GNRI status and clinicopathological factors in elderly patients with stage II colorectal cancer

From: Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study

 

GNRIhigh (n = 147)

GNRIlow (n = 201)

Pvalue

Age (median)

81 (75–95)

83 (75–98)

 < 0.001

Sex

  Male

69 (46.9%)

92 (45.8%)

0.913

  Female

78 (53.1%)

109 (54.2%)

 

ECOG PS

  0, 1

121 (82.3%)

113 (56.2%)

 < 0.001

  2, 3, 4

26 (17.7%)

88 (43.8%)

 

BMI

23.1 (17.8–28.7)

19.5 (11.7–28.1)

 < 0.001

ALB

3.9 (2.8–4.9)

3.1 (1.5–4.8)

 < 0.001

CRP

0.16 (0.02–10.30)

0.69 (0.02–34.70)

 < 0.001

Preoperative CEA

3.6 (0.8–366.0)

4.9 (1.0–886.3)

0.015

Preoperative CA19-9

11.0 (0–8882.2)

9.1 (0–5782.0)

0.457

Location

  Colon

116 (78.9%)

160 (79.6%)

0.894

  Rectum

31 (21.1%)

41 (20.4%)

 

Obstruction

  Absent

127 (86.4%)

135 (67.2%)

 < 0.001

  Present

20 (13.6%)

66 (32.8%)

 

Perforation

  Absent

143 (97.3%)

192 (95.5%)

0.569

  Present

4 (2.7%)

9 (4.5%)

 

Histology a

  tub

135 (91.8%)

176 (87.6%)

0.222

  por, muc

12 (8.2%)

25 (12.4%)

 

Pathologic T stage b

  T1, T2, T3

133 (90.5%)

152 (75.6%)

 < 0.001

  T4

14 (9.5%)

49 (24.4%)

 

Lymphatic invasion c

  Ly0, 1a

129 (87.8%)

154 (76.6%)

0.008

  Ly1b, c

18 (12.2%)

47 (23.4%)

 

Vascular invasion d

  V0, 1a

110 (74.8%)

154 (76.6%)

0.706

  V1b, c

37 (25.2%)

47 (23.4%)

 

Adjuvant chemotherapy

  Absent

128 (87.1%)

179 (89.1%)

0.615

  Present

19 (12.9%)

22 (10.9%)

 
  1. GNRI Geriatric Nutritional Risk Index, ECOG PS Eastern Cooperative Oncology Group Performance Status, BMI Body mass index, ALB Serum albumin level, CRP C-reactive protein, CEA Carcinoembryonic antigen, CA19-9 Carbohydrate antigen 19–9
  2. aHistology: tub, tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; muc, mucinous adenocarcinoma
  3. bPathologic T stage: T1, Tumor is confined to the submucosa and does not invade the muscularis propria (MP); T2, Tumor invasion to, but not beyond, the MP; T3, Tumor invades beyond the MP. In sites with serosa, the tumor grows into the subserosa. In sites with no serosa, the tumor grows into the adventitia; T4, Tumor invades or perforates the serosa or directly invades other organs or structures
  4. cLymphatic invasion: L1a, Minimal lymphatic invasion; L1b, Moderate lymphatic invasion; L1c, Severe lymphatic invasion
  5. dVascular invasion: V1a, Minimal venous invasion; V1b, Moderate venous invasion; V1c, Severe venous invasion